Research Article 
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme
A. K. Sjolie, R. Klein, M. Porta, T. Orchard, J. Fuller, H. H. Parving, R. Bilous, S. Aldington and N. Chaturvedi
Diabetic Medicine, 2011, 28(3), 345-351. DOI: 10.1111/j.1464-5491.2010.03210.x
Abstract
Objective: To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes. Methods: This was a multicenter randomized clinical trial. The progression analysis included 893 patients with Type 1 diabetes and 526 patients with Type 2 diabetes with retinal microaneurysms only at baseline. For regression, 438 with Type 1 and 216 with Type 2 diabetes qualified. Microaneurysms were scored from yearly retinal photographs according to the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Retinopathy progression and regression was defined as two or more step change on the ETDRS scale from baseline. Patients were normoalbuminuric, and normotensive with Type 1 and Type 2 diabetes or treated hypertensive with Type 2 diabetes. They were randomized to treatment with candesartan 32 mg daily or placebo and followed for 4.6 years. Results: A higher microaneurysm score at baseline predicted an increased risk of retinopathy progression (HR per microaneurysm score 1.08, P < 0.0001 in Type 1 diabetes; HR 1.07, P = 0.0174 in Type 2 diabetes) and reduced the likelihood of regression (HR 0.79, P < 0.0001 in Type 1 diabetes; HR 0.85, P = 0.0009 in Type 2 diabetes), all adjusted for baseline variables and treatment. Candesartan reduced the risk of microaneurysm score progression. Conclusions: Microaneurysm counts are important prognostic indicators for worsening of retinopathy, thus microaneurysms are not benign. Treatment with renin-angiotensin system inhibitors is effective in the early stages and may improve mild diabetic retinopathy. Microaneurysm scores may be useful surrogate endpoints in clinical trials.
ASCI-ID: 109-366
Similar Articles
Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis
Diabetic Medicine, 2011, 28(10), 1182-1187. DOI: 10.1111/j.1464-5491.2011.03341.x
Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4Diabetic Medicine, 2008, 25(5), 536-542. DOI: 10.1111/j.1464-5491.2008.02423.x
Health utility values associated with diabetic retinopathyDiabetic Medicine, 2008, 25(5), 618-624. DOI: 10.1111/j.1464-5491.2008.02430.x
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS studyDiabetic Medicine, 2009, 26(5), 460-465. DOI: 10.1111/j.1464-5491.2009.02719.x
Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age populationDiabetic Medicine, 2009, 26(5), 489-492. DOI: 10.1111/j.1464-5491.2009.02718.x
Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programmeDiabetic Medicine, 2009, 26(10), 1040-1047. DOI: 10.1111/j.1464-5491.2009.02820.x
Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetesDiabetic Medicine, 2010, 27(4), 431-435.
Is risk of diabetic retinopathy lower in Australia’s Greek-born migrants?Diabetic Medicine, 2010, 27(6), 660-665. DOI: 10.1111/j.1464-5491.2010.03005.x
Increased levels of monokine induced by interferon-γ (Mig) in the vitreous of patients with diabetic retinopathyDiabetic Medicine, 2008, 25(7), 875-877. DOI: 10.1111/j.1464-5491.2008.02466.x
Reliability of screening methods for diabetic retinopathyDiabetic Medicine, 2009, 26(8), 783-790. DOI: 10.1111/j.1464-5491.2009.02778.x
Blood pressure control and awareness among patients with diabetes and hypertension attending a tertiary ophthalmic clinicDiabetic Medicine, 2009, 26(1), 34-39. DOI: 10.1111/j.1464-5491.2008.02614.x
Diabetic retinopathy screening: a systematic review of the economic evidenceDiabetic Medicine, 2010, 27(3), 249-256. DOI: 10.1111/j.1464-5491.2009.02870.x
Socio-economic and ethnic inequalities in diabetes retinal screeningDiabetic Medicine, 2010, 27(3), 282-288. DOI: 10.1111/j.1464-5491.2010.02946.x
Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem StudyDiabetic Medicine, 2010, 27(10), 1130-1137. DOI: 10.1111/j.1464-5491.2010.03080.x
Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathyDiabetic Medicine, 2011, 28(6), 741-746. DOI: 10.1111/j.1464-5491.2011.03273.x
Do type 2 diabetes patients without diabetic retinopathy or subjects with impaired fasting glucose have impaired colour vision? The Okubo Color Study ReportDiabetic Medicine, 2011, 28(7), 865-871. DOI: 10.1111/j.1464-5491.2011.03290.x
External quality assurance for image grading in the Scottish Diabetic Retinopathy Screening ProgrammeDiabetic Medicine, 2012, 29(6), 776-783. DOI: 10.1111/j.1464-5491.2011.03504.x
Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experimentDiabetic Medicine, 2012, 29(7), 869-877. DOI: 10.1111/j.1464-5491.2012.03636.x
Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screeningDiabetic Medicine, 2012, 29(7), 878-885. DOI: 10.1111/j.1464-5491.2012.03637.x
Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countriesDiabetic Medicine, 2013, 30(4), 387-398. DOI: 10.1111/dme.12119